Cargando…

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy

BACKGROUND: Given the low chance of response to neoadjuvant chemotherapy (NACT) in luminal breast cancer (LBC), the identification of predictive factors of pathological complete response (pCR) represents a challenge. A multicenter retrospective analysis was performed to develop and validate a predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garufi, Giovanna, Carbognin, Luisa, Sperduti, Isabella, Miglietta, Federica, Dieci, Maria Vittoria, Mazzeo, Roberta, Orlandi, Armando, Gerratana, Lorenzo, Palazzo, Antonella, Fabi, Alessandra, Paris, Ida, Franco, Antonio, Franceschini, Gianluca, Fiorio, Elena, Pilotto, Sara, Guarneri, Valentina, Puglisi, Fabio, Conte, Pierfranco, Milella, Michele, Scambia, Giovanni, Tortora, Giampaolo, Bria, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017935/ https://www.ncbi.nlm.nih.gov/pubmed/36936199 http://dx.doi.org/10.1177/17588359221138657

Ejemplares similares

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
por: Carbognin, Luisa, et al.
Publicado: (2020)

Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.
por: Garufi, Giovanna, et al.
Publicado: (2020)

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
por: Mastrantoni, Luca, et al.
Publicado: (2023)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
por: Garufi, Giovanna, et al.
Publicado: (2022)

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
por: Carbognin, Luisa, et al.
Publicado: (2019)

Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study
por: Trestini, Ilaria, et al.
Publicado: (2021)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage ‘pure’ and ‘mixed’ lobular breast cancer
por: Carbognin, Luisa, et al.
Publicado: (2016)

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome
por: Trestini, Ilaria, et al.
Publicado: (2020)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
por: Mastrantoni, Luca, et al.
Publicado: (2023)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response
por: Pasqualoni, Mariangela, et al.
Publicado: (2023)

Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
por: Bonomi, Maria, et al.
Publicado: (2011)

An overview of immune checkpoint inhibitors in breast cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis
por: Orlandi, Armando, et al.
Publicado: (2021)

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations
por: Peretti, U., et al.
Publicado: (2016)

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital
por: Cesario, Alfredo, et al.
Publicado: (2021)

Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting
por: Franco, Antonio, et al.
Publicado: (2023)

Oligometastatic Breast Cancer: How to Manage It?
por: Barberi, Vittoria, et al.
Publicado: (2021)

Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis
por: Bria, E., et al.
Publicado: (2016)

Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
por: Sposito, Marco, et al.
Publicado: (2023)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
por: Miglietta, F., et al.
Publicado: (2022)

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]
por: Miglietta, F., et al.
Publicado: (2022)

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2016)

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
por: Ferrara, Miriam Grazia, et al.
Publicado: (2020)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lgj82rf09aj8p5kmq4kodgd9a1